Bristol-Myers Squibb (BMY) Announces Positive Data From the Pivotal Phase 3 POETYK PsA-1 Trial

Bristol-Myers Squibb Company (NYSE:BMY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. On June 11, Bristol-Myers Squibb Company (NYSE:BMY) announced positive data from the pivotal Phase 3 POETYK PsA-1 trial that investigated the safety and efficacy of Sotyktu in adults with active psoriatic arthritis (PsA) who did not previously receive treatment through a biologic disease-modifying antirheumatic drug (bDMARD). The trial met its primary endpoint, demonstrating that more patients treated with Sotyktu achieved an ACR20 response, or at least a 20% improvement in signs and symptoms of disease, compared to placebo at Week 16.

A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution.

Sotyktu’s safety profile through 16 weeks of treatment remained consistent with previous reports throughout its clinical trials, including the Phase 3 POETYK PsA-2 trial and the Phase 3 moderate-to-severe plaque psoriasis (PsO) clinical trials.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.